Gemtuzumab Ozogamicin

No information is available on the clinical use of gemtuzumab ozogamicin during breastfeeding. Because gemtuzumab is a large protein molecule with a molecular weight of about 152,000 Da the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] Ozogamicin (N-acetyl gamma calicheamicin) is a small-molecule that causes double-stranded DNA that might enter milk and be absorbed by the infant. Because of the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends that women not breastfeed during treatment and for at least 1 month after the final dose.